While the MedicalXpress article effectively summarizes a Tulane University retrospective cohort study published in JAMA Network Open, it stops short of contextualizing the findings within syphilis's long-underestimated vascular pathology and the broader syndemic patterns now unfolding across the U.S. The Tulane analysis—drawing on electronic health records from 1,469 adults with syphilis and 7,345 matched controls across three New Orleans hospitals (2011–2025)—found that later-stage infection (lasting longer than one year) was associated with roughly doubled risk of aortic aneurysm/dissection, 53% higher ischemic stroke risk, 92% higher hemorrhagic stroke risk, 31% higher myocardial infarction risk, and 28% higher peripheral artery disease after adjustment. This was an observational study, not an RCT; despite attempts to exclude baseline cardiovascular disease and control for confounders, residual bias from unmeasured factors such as socioeconomic status, HIV co-infection prevalence, and exact treatment adherence remains possible. Sample size is moderate for a single health system, and generalizability beyond the high-prevalence South is uncertain. No conflicts of interest were reported.

What the original coverage missed is the historical through-line and the modern social drivers. Before penicillin, tertiary syphilis caused cardiovascular complications in an estimated 10–15% of untreated cases, with Treponema pallidum triggering obliterative endarteritis, aortitis, and aneurysm formation. The Tulane results suggest this pathway never disappeared—it was merely masked by earlier detection and treatment. Contemporary resurgence has reversed decades of progress: CDC surveillance data from 2018–2023 document an 80%+ national increase in primary and secondary syphilis, with Southern states bearing disproportionate burden linked to structural factors including poverty, incarceration, reduced STI clinic funding post-2020, and methamphetamine/opioid use disrupting sexual networks.

A second key source, the CDC's 2022 STD Surveillance Report, reveals that rates among men who have sex with men and among Black and Hispanic populations are several-fold higher, patterns also seen in the Tulane cohort's New Orleans setting. A third reference point is a 2019 systematic review in Clinical Infectious Diseases by Ghanem et al. analyzing modern cohorts with neurosyphilis and cardiovascular involvement; that review similarly documented persistent inflammatory signatures (elevated CRP, IL-6) even after serologic cure, supporting the Tulane authors' hypothesis that chronic inflammation accelerates atherosclerosis and endothelial damage. The MedicalXpress piece underplays this mechanistic continuity and fails to note that current single-dose benzathine penicillin may clear bacteremia yet leave subclinical vascular remodeling unaddressed in late latent cases.

The deeper public-health crisis lies at the intersection of sexual health stigma and cardiovascular prevention. Providers treating high-risk patients rarely screen for syphilis as a CV risk enhancer akin to HIV or periodontal disease, despite overlapping inflammatory pathways. With cardiovascular disease remaining the nation's leading cause of death, the Tulane data—combined with historical Oslo and Tuskegee cohort insights—indicate that undetected or inadequately treated syphilis functions as a modifiable accelerator of stroke and heart attack. Integrated care models that combine routine syphilis serology with lipid and inflammatory biomarker monitoring in emergency departments and safety-net clinics could mitigate this. Future prospective studies with imaging endpoints (e.g., aortic PET-CT) and rigorous documentation of treatment timing are urgently required to move from association toward causation and intervention. Until then, this resurgence represents not merely a failure of sexual health policy but a silent contributor to the country's cardiometabolic burden.